13F Holdings
中文EN

IRIX IRIDEX CORP

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1006045 · Fiscal year ends 01/03

Financial factors as of 2026-07-04 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.7%
TTM net income YoY34.9%
TTM EPS YoY37.5%
Revenue 3-yr CAGR-2.9%
Net income 3-yr CAGR—

Margins

Gross margin35.9%
Operating margin-5.4%
Net margin-6.9%
FCF margin-3.9%
EBITDA margin-4.5%

Returns

ROE-73.1%
ROA-12.1%
ROIC (approx.)—
Asset turnover1.75x

Leverage & solvency

Liabilities / assets86.6%
Debt / equity0.00x
Current ratio1.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.49x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-01-03FY20242024-12-28FY20232023-12-30FY20222022-12-31FY20212022-01-01
Income statement
Revenue$52.67M$48.67M$51.87M$56.97M$53.90M
Cost of revenue$33.45M$29.17M$30.06M$31.60M$31.07M
Gross profit$19.23M$19.50M$21.81M$25.37M$22.83M
R&D expense$3.67M$5.45M$6.83M$7.17M$6.87M
SG&A expense$7.73M$9.78M$8.75M$7.56M$8.86M
Operating income-$2.57M-$8.30M-$10.01M-$7.54M-$7.53M
Interest expense$58,000$146,000———
Pretax income-$4.38M-$8.84M-$9.48M-$7.48M-$5.18M
Income tax$57,000$68,000$90,000$65,000$40,000
Net income-$4.44M-$8.91M-$9.57M-$7.55M-$5.22M
EBITDA-$2.05M-$7.72M-$8.91M-$7.06M-$6.73M
EPS (basic)-0.26-0.54-0.59-0.47-0.34
EPS (diluted)-0.26-0.54-0.59-0.47-0.34
Weighted avg. shares (diluted)16.93M16.44M16.13M15.94M15.42M
Balance sheet
Cash & equivalents$6.03M$2.39M$7.03M$13.92M$23.85M
Receivables$7.61M$5.95M$6.73M$6.23M$6.61M
Inventory$7.88M$10.82M$9.91M$10.61M$7.61M
Current assets$25.25M$23.56M$27.45M$35.77M$42.25M
PP&E, net$58,000$115,000$351,000$462,000$428,000
Goodwill$965,000$965,000$965,000$965,000$965,000
Intangibles$984,000$1.31M$1.64M$1.98M$2.21M
Total assets$29.15M$29.14M$34.44M$42.29M$48.69M
Current liabilities$13.21M$16.56M$12.97M$12.45M$12.65M
Short-term debt—$1.70M———
Long-term debt—$1.00M———
Total debt—$2.70M———
Total liabilities$24.23M$27.04M$24.91M$25.06M$25.39M
Shareholders' equity$4.92M$2.10M$9.52M$17.23M$23.30M
Net debt—$313,000———
Shares outstanding17.31M16.64M16.25M15.99M15.88M
Cash flow statement
Operating cash flow-$2.12M-$7.29M-$6.75M-$9.52M$8.22M
Capital expenditure$143,000$13,000$109,000$286,000$213,000
Free cash flow-$2.26M-$7.30M-$6.85M-$9.80M$8.00M
Investing cash flow-$143,000-$13,000-$109,000-$286,000-$5.56M
Financing cash flow$5.96M$2.60M-$5,000-$73,000$9.47M
Depreciation & amortization$523,000$584,000$1.10M$485,000$803,000
Stock-based compensation$775,000$1.24M$1.65M$1.62M$1.63M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.